Wells Fargo analyst Timothy Daley maintains Charles River (NYSE:CRL) with a Overweight and lowers the price target from $325 to $300.
Apogee Therapeutics Advances in Clinical Trials for Promising Treatments in Inflammatory Diseases, and Reported Net Loss of $(32.1)M, Held $816.2M in Cash
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma
